embalaje : 1mLx10mM(inDMSO)
Teléfono : +1 850 650 7790
Synonyms:
| Description | Trolox is a vitamin E analogue, used in reducing oxidative stress or damage. |
| Targets & IC50 | MCF-7 cells:> 300 μM, RAW 264.7 cells:30 μM, MT-4 cells:200 μM, Erythrocyte:101 μM, U-937 cells:300 μM, HL-60 cells:0.3 μg/mL, SH-SY5Y cells:82.3 μM, RPMI8226 cells:> 300 μM, Melan-a cells:300 μM, HepG2 cells:> 300 μM |
| In vitro | METHODS: Human cervical cancer cells HeLa were treated with Trolox (2.5-160 µM) for 24 h and cell viability was measured using MTT assay. RESULTS: Cell viability decreased dose-dependently, with the maximum effect observed at 160 µM Trolox. [1] METHODS: Human skin fibroblasts were treated with Trolox (0.5 mM) for 96 h. The expression levels of target proteins were measured by Western Blot. RESULTS: Trolox increased the mitochondrial levels of Mfn2 in primary human skin fibroblasts without affecting these levels of Drp1 and hFis1. [2] |
| In vivo | METHODS: To investigate the neuroprotective effects, Trolox (50 mg/kg) was intraperitoneally injected once a day for ten days into an MPTP-induced Parkinson's disease mouse model. RESULTS: Trolox may exert neuroprotective effects on dopaminergic neurons against MPTP-induced oxidative stress, neuroinflammation, motor dysfunction and neurodegeneration. [3] |
| Molecular Weight | 250.29 |
| Formula | C14H18O4 |
| Cas No. | 53188-07-1 |
| Smiles | O=C(C1(C)CCC2=C(O1)C(C)=C(C)C(O)=C2C)O |
| Relative Density. | 1.219g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (199.77 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (19.98 mM), Solution. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
